NBIX NEUROCRINE BIOSCIENCES INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 914475 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY38.0%
TTM net income YoY64.1%
TTM EPS YoY60.9%
Revenue 3-yr CAGR27.5%
Net income 3-yr CAGR54.4%
Margins
Gross margin97.8%
Operating margin24.0%
Net margin19.0%
FCF margin28.1%
EBITDA margin24.8%
Returns
ROE20.4%
ROA14.2%
ROIC (approx.)22.7%
Asset turnover0.75x
Leverage & solvency
Liabilities / assets31.1%
Debt / equity0.00x
Current ratio2.04x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.52x
Accruals ratio-7.3%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B |
| Cost of revenue | $52.10M | $34.00M | $39.70M | $23.20M | $14.30M |
| Gross profit | $2.81B | $2.32B | $1.85B | $1.47B | $1.12B |
| R&D expense | $1.02B | $731.10M | $565.00M | $463.80M | $328.10M |
| SG&A expense | $1.16B | $1.01B | $887.60M | $752.70M | $583.30M |
| Operating income | $619.10M | $570.50M | $250.90M | $249.00M | $102.50M |
| Interest expense | — | — | $4.60M | $7.10M | $25.80M |
| Pretax income | $705.40M | $486.00M | $332.10M | $213.90M | $101.40M |
| Income tax | $226.80M | $144.70M | $82.40M | $59.40M | $11.80M |
| Net income | $478.60M | $341.30M | $249.70M | $154.50M | $89.60M |
| EBITDA | $645.10M | $594.00M | $268.70M | $264.10M | $113.40M |
| EPS (basic) | 4.81 | 3.40 | 2.56 | 1.61 | 0.95 |
| EPS (diluted) | 4.67 | 3.29 | 2.47 | 1.56 | 0.92 |
| Weighted avg. shares (diluted) | 102.50M | 103.70M | 101.00M | 98.90M | 97.90M |
| Balance sheet | |||||
| Cash & equivalents | $713.00M | $241.00M | $259.10M | $270.70M | $344.00M |
| Short-term investments | $767.40M | $843.10M | $780.50M | $726.40M | $370.50M |
| Receivables | $686.80M | $479.10M | $439.30M | $350.00M | $185.50M |
| Inventory | $69.00M | $57.40M | $38.30M | $35.10M | $30.50M |
| Current assets | $2.52B | $1.72B | $1.61B | $1.45B | $972.80M |
| PP&E, net | $89.80M | $82.60M | $70.80M | $58.60M | $58.60M |
| Goodwill | $6.10M | $5.70M | $5.80M | $5.40M | $0 |
| Intangibles | $4.70M | $36.50M | $35.50M | $37.20M | $0 |
| Total assets | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B |
| Current liabilities | $743.40M | $507.70M | $654.80M | $537.70M | $245.80M |
| Total liabilities | $1.38B | $1.13B | $1.02B | $660.90M | $698.50M |
| Shareholders' equity | $3.25B | $2.59B | $2.23B | $1.71B | $1.37B |
| Shares outstanding | 100.10M | 99.40M | 98.70M | 96.50M | 94.90M |
| Cash flow statement | |||||
| Operating cash flow | $782.70M | $595.40M | $389.90M | $339.40M | $256.50M |
| Capital expenditure | $34.00M | $38.20M | $28.30M | $16.50M | $23.40M |
| Free cash flow | $748.70M | $557.20M | $361.60M | $322.90M | $233.10M |
| Investing cash flow | -$264.40M | -$126.80M | -$467.10M | -$177.10M | -$130.20M |
| Financing cash flow | -$38.30M | -$486.70M | $65.30M | -$234.30M | $27.40M |
| Depreciation & amortization | $26.00M | $23.50M | $17.80M | $15.10M | $10.90M |
| Stock-based compensation | $217.90M | $195.50M | $194.30M | $173.10M | $134.20M |
| Share buybacks | $167.70M | $300.00M | $0 | $0 | — |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.